

Steven D Edland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10581146/publications.pdf>

Version: 2024-02-01

50
papers

2,119
citations

279487

23
h-index

288905

40
g-index

50
all docs

50
docs citations

50
times ranked

3054
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular Dementia in a Population-Based Autopsy Study. Archives of Neurology, 2003, 60, 569.	4.9	194
2	Dementia and Alzheimer Disease Incidence Rates Do Not Vary by Sex in Rochester, Minn. Archives of Neurology, 2002, 59, 1589.	4.9	159
3	ADCS Prevention Instrument Project: Assessment of Instrumental Activities of Daily Living for Community-dwelling Elderly Individuals in Dementia Prevention Clinical Trials. Alzheimer Disease and Associated Disorders, 2006, 20, S152-S169.	0.6	153
4	Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer's Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells. Cell Stem Cell, 2015, 16, 373-385.	5.2	143
5	Clinical and Neuropathological Characteristics of Hippocampal Sclerosis. Archives of Neurology, 2002, 59, 1099.	4.9	136
6	Pulse Pressure in Relation to Tau-Mediated Neurodegeneration, Cerebral Amyloidosis, and Progression to Dementia in Very Old Adults. JAMA Neurology, 2015, 72, 546.	4.5	101
7	Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology, 2013, 81, 2024-2027.	1.5	89
8	Survival Study of Vascular Dementia in Rochester, Minnesota. Archives of Neurology, 2003, 60, 85.	4.9	85
9	Reduction of SorLA/LR11, a Sorting Protein Limiting β -Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid. Archives of Neurology, 2009, 66, 448-57.	4.9	79
10	Incidence and Causes of Nondegenerative Nonvascular Dementia. Archives of Neurology, 2006, 63, 218.	4.9	77
11	Polymorphisms at the Werner locus: II. 1074Leu/Phe, 1367Cys/Arg, longevity, and atherosclerosis. American Journal of Medical Genetics Part A, 2000, 95, 374-380.	2.4	66
12	Incidence of Vascular Dementia in Rochester, Minn, 1985-1989. Archives of Neurology, 2002, 59, 1605.	4.9	66
13	Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians. , 1999, 82, 399-403.		62
14	Power Calculations for Clinical Trials in Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 369-377.	1.2	59
15	DNA methylation changes associated with Parkinson's disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics, 2019, 14, 365-382.	1.3	58
16	The cognitive abilities screening instrument (CASI): data from a cohort of 2524 cognitively intact elderly. , 1999, 14, 882-888.		44
17	Insulin-Degrading Enzyme, Apolipoprotein E, and Alzheimer's Disease. Journal of Molecular Neuroscience, 2004, 23, 213-218.	1.1	42
18	Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 269-277.	0.6	42

#	ARTICLE	IF	CITATIONS
19	Exploratory Study of Apolipoprotein E ϵ 4 Genotype and Risk of Alzheimer's Disease in Mexican Hispanics. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 1038-1040.	1.3	36
20	Attitudes Toward Use of Nursing Homes and Home Care in Older Japanese-Americans. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 769-777.	1.3	34
21	Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. , 2000, 19, 1617-1629.		33
22	Evaluation of Selection Bias in an Incident-Based Dementia Autopsy Case Series. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 67-73.	0.6	33
23	Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 11-18.	1.8	30
24	Geographically Overlapping Alzheimer's Disease Registries: Comparisons and Implications. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1995, 8, 203-208.	1.2	29
25	Mitochondrial Genetic Variants and Alzheimer Disease: A Case-Control Study of the T4336C and G5460A Variants. <i>Alzheimer Disease and Associated Disorders</i> , 2002, 16, 1-7.	0.6	26
26	Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. <i>Pharmaceutical Statistics</i> , 2015, 14, 418-426.	0.7	24
27	Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2015, 11, 1069-1079.	0.4	22
28	Genetic association studies in Alzheimer's disease research: challenges and opportunities. <i>Statistics in Medicine</i> , 2004, 23, 169-178.	0.8	21
29	NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 159-164.	0.6	20
30	The net effect of alternative allocation ratios on recruitment time and trial cost. <i>Clinical Trials</i> , 2009, 6, 126-132.	0.7	19
31	Smokers who report smoking but do not consider themselves smokers: a phenomenon in need of further attention: Table A1. <i>Tobacco Control</i> , 2015, 24, 400-403.	1.8	19
32	Improved Statistical Power of Alzheimer Clinical Trials by Item-Response Theory. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 187-191.	0.6	18
33	Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 75, 169-177.	1.5	13
34	Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1539-1548.	1.2	11
35	Proof of concept demonstration of optimal composite MRI endpoints for clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 177-181.	1.8	9
36	Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 508-514.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Blomqvist revisited: how and when to test the relationship between level and longitudinal rate of change. , 2000, 19, 1441-1452.		8
38	Contributions to composite sampling. Environmental and Ecological Statistics, 2001, 8, 171-180.	1.9	8
39	Design of pilot studies to inform the construction of composite outcome measures. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 213-218.	1.8	8
40	Sex and <i>APOE</i> ϵ 4 modify the effect of cardiovascular risk on tau in cognitively normal older adults. Brain Communications, 2022, 4, fca035.	1.5	8
41	Differential blood DNA methylation across Lewy body dementias. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12156.	1.2	7
42	Community memory screening as a strategy for recruiting older adults into Alzheimer's disease research. Alzheimer's Research and Therapy, 2020, 12, 78.	3.0	4
43	Power formulas for mixed effects models with random slope and intercept comparing rate of change across groups. International Journal of Biostatistics, 2022, 18, 173-182.	0.4	4
44	Referral bias in Alzheimer's disease. Journal of Clinical Epidemiology, 1997, 50, 365.	2.4	3
45	Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cyl/Arg, and its stability in a population of Finnish centenarians. , 1999, 82, 399.		3
46	The cognitive abilities screening instrument (CASI): data from a cohort of 2524 cognitively intact elderly. , 1999, 14, 882.		3
47	Polymorphisms at the Werner locus: II. 1074Leu/Phe, 1367Cys/Arg, longevity, and atherosclerosis. , 2000, 95, 374.		2
48	Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. Pharm Stat. 18 (2):239-47, 2019, DOI: 10.1002/pst.1920. Pharmaceutical Statistics, 2020, 19, 492-493.	0.7	0
49	Power Calculations for Two-Wave, Change from Baseline to Follow-Up Study Designs. International Journal of Statistics in Medical Research, 2012, 1, 45-50.	0.5	0
50	The MAX Statistic is Less Powerful for Genome Wide Association Studies Under Most Alternative Hypotheses. International Journal of Statistics in Medical Research, 2017, 6, 144-151.	0.5	0